Skip to main content

FDA 21 CFR Part 11 & E-Signature Compliance Guides

Expert guides on FDA 21 CFR Part 11, ALCOA+ data integrity, GxP compliance, and electronic signature requirements for clinical trials, pharma, and life sciences.

Regulatory ComplianceLatest

CIOMS XIV AI Pharmacovigilance Framework: Mapping to 21 CFR Part 11 Attribution and Audit Trails

CIOMS Working Group XIV's AI pharmacovigilance framework rests on principles 21 CFR Part 11 already regulates. Here's how attribution and audit trail requirements carry over to AI-assisted signal detection.

July 13, 202610 min read

All Articles

Clinical Trials

IRB Electronic Signature Requirements: What Part 11 Demands for Approval Letters

IRB and ethics committee records are subject to FDA Part 11 the moment they go electronic. This guide covers approval letter signatures, continuing review timing, member vote attribution, and common gaps in electronic IRB signature architecture.

July 7, 20268 min read
Regulatory Compliance

GMP Batch Release E-Signatures: The QA Release Sign-Off Workflow Under Part 11

The batch disposition sign-off is the highest-stakes signature event in GMP pharmaceutical manufacturing. This guide covers the electronic signature workflow for QA release: the four prerequisite reviews before lot release, the audit trail review step FDA investigators specifically target, batch release electronic signature requirements under 21 CFR 211.192 and Part 11, EU GMP Annex 11 Qualified Person obligations, and why general e-signature tools consistently fail GMP batch release inspections.

June 30, 202612 min read
Clinical Trials

eTMF E-Signature Requirements: FDA Part 11, ICH E6(R3), and the Four Compliance Gaps

Electronic Trial Master File (eTMF) systems are subject to FDA 21 CFR Part 11 because the TMF is required by predicate rules. This guide covers which eTMF documents require electronic signatures, what ICH E6(R3) changed for validation requirements, the four Part 11 controls most often deficient in eTMF platforms, and what to verify in a platform before committing to it for your trial program.

June 29, 202613 min read
Regulatory Compliance

EU GMP Annex 22: AI Governance in GxP Systems — What Pharma Needs to Know

EMA is developing EU GMP Annex 22 as a dedicated companion to the Annex 11 revision, specifically governing AI and algorithmic systems in GxP environments. This guide covers what Annex 22 will require: AI attribution in audit trails, algorithm versioning, human oversight documentation, training data traceability, and how this aligns with FDA's parallel AI framework. Updated June 2026 alongside the Annex 11 finalization window.

June 27, 202611 min read
Clinical Trials

Informed Consent E-Signatures: FDA Part 11 Requirements

Electronic signatures on informed consent forms must satisfy both 21 CFR Part 50 and 21 CFR Part 11. This guide covers what the audit trail must capture for each consent event, re-consent workflows, IRB qualification questions, and the three most common 483 findings at investigator sites using electronic consent.

June 22, 20269 min read
Regulatory Compliance

21 CFR Part 11 Applicability Assessment: Predicate Rules and When Part 11 Applies

21 CFR Part 11 applies only when a predicate rule requires a record and that record is maintained electronically. This guide explains the two-part applicability test, what a predicate rule is, the six elements of a compliant applicability assessment, and the three most common errors FDA inspectors find -- including hybrid record misclassification and failure to reassess after system changes.

June 21, 202611 min read
Regulatory Compliance

EU GMP Annex 11 Clause 3 Supplier Qualification: What Pharma Must Document Before Deployment

EU GMP Annex 11 Clause 3 requires a formal supplier qualification assessment before deploying any e-signature platform. This guide covers the six assessment elements, what documentation to request from vendors, and how to structure the assessment report for EU GMP audit readiness.

June 15, 202610 min read
Clinical Trials

Remote Monitoring Visits and Electronic Records: What ICH E6(R3) Requires for E-Signatures

ICH E6(R3) formally recognizes remote and risk-based monitoring as GCP-compliant, but the electronic records and e-signature obligations for monitoring visit reports, delegation of authority logs, and follow-up letters are unchanged. This guide covers what 21 CFR Part 11 requires for electronically signed remote monitoring records, the EDC boundary rule for remote source data verification, ICH E6(R3) Section 5.5.3 sponsor oversight obligations, and the four compliance gaps most common in remote monitoring programs.

June 15, 202613 min read
Company

Certivo is Now Klyverity

Certivo is now Klyverity. Same company, same team, same FDA 21 CFR Part 11 platform. Your account, data, signed records, and agreements all carry over.

June 12, 20264 min read
Regulatory Compliance

Part 11 Audit Trail Review SOP: Required Frequency and Elements

How often must Part 11 audit trails be reviewed, and what must the SOP say? Frequency by predicate rule, the six required SOP elements, and top FDA findings.

June 8, 202613 min read
Regulatory Compliance

21 CFR Part 11 vs EU GMP Annex 11: Side-by-Side Compliance Guide (2026)

FDA 21 CFR Part 11 and EU GMP Annex 11 share a strong technical foundation but diverge in three areas that matter for dual-jurisdiction organizations: audit trail scope (Clause 9 adds exports and archival), supplier qualification (Clause 3 requires formal assessment), and periodic system review (Clause 11). Updated June 2026 with the 2025 Annex 11 draft comparison and preparation steps before finalization.

June 6, 202614 min read
Regulatory Compliance

21 CFR Part 11 Audit Trail Requirements: What Your E-Signature System Must Log

FDA 21 CFR Part 11 Section 11.10(e) requires secure, computer-generated, time-stamped audit trails for all electronic signature systems. This guide covers the seven data elements every audit entry must capture, what triggers a log entry, how administrator actions must be handled, tamper-evidence requirements, and the five most common audit trail gaps FDA inspectors find.

June 1, 202613 min read
Regulatory Compliance

EU GMP Annex 11 2025 Draft: Electronic Signature Changes and MFA Requirement

The EMA's 2025 consultation draft of EU GMP Annex 11 makes multi-factor authentication explicitly mandatory for electronic signatures in GxP systems — the most significant update since the 2011 publication. Updated June 2026: finalization window now active, Annex 22 companion document for AI governance in development alongside it. Covers Clause 12.1 MFA requirement, Clause 9 expanded audit trail scope, Clause 16 AI attribution, how the draft compares to FDA Part 11 Section 11.200(a), and preparation steps before finalization.

May 23, 202612 min read
Regulatory Compliance

GxP Electronic Records: What FDA, EMA, and ICH Regulations Actually Require in 2026

GxP compliance means four different regulatory frameworks with different text and different enforcement bodies. This guide cites the actual regulatory text — FDA 21 CFR Part 11 Section 11.10(e), EU GMP Annex 11 (2025 draft) Clause 12.1, and ICH E6(R3) Section 5.5.3 — showing exactly what each requires for electronic records, audit trails, and electronic signatures. Includes a 7-question vendor evaluation table testing claims against the regulatory text.

May 20, 202614 min read
Clinical Trials

Electronic Signatures for Clinical Trials: Site Coordinator, Sponsor, and CRO Responsibilities

Electronic signatures in clinical trials are a shared obligation across three regulated parties. This guide breaks down the specific Part 11 responsibilities of sponsors, CROs, and investigator sites under the FDA's October 2024 final guidance, covering vendor qualification, non-repudiation letters, delegation of authority logs, authentication at signing, and the documents most likely to fail at each level. Updated June 2026 with ESG NextGen portal submission change for non-repudiation letters.

May 18, 202614 min read
Regulatory Compliance

GxP Compliant Electronic Signatures: What the Regulations Require and How to Select a Platform

GxP compliant electronic signatures must satisfy FDA 21 CFR Part 11 as a foundation, then layer on discipline-specific requirements from GMP, GLP, and GCP. This guide explains what each regulation actually requires, how the February 2026 QMSR implementation changed the GMP picture for medical devices, what EU GMP Annex 11 adds for multi-regional organizations, and a 10-question technical checklist for evaluating whether a platform is genuinely GxP compliant versus simply claiming it.

May 17, 202613 min read
Regulatory Compliance

HIPAA and 21 CFR Part 11: Dual Compliance for Healthcare Research

Healthcare research sites face simultaneous obligations under HIPAA and 21 CFR Part 11. Updated May 2026 to cover the March 2026 CMS final rule establishing the first HIPAA-adopted standard for electronic signatures in claims attachments — and what it means for organizations that must satisfy both federal frameworks at once. Covers the BAA requirement, two-component authentication at signing, signature meaning, non-repudiation letter obligations, and dual-compliance vendor selection.

May 11, 202612 min read
Clinical Trials

21 CFR Part 11 for Small Clinical Research Sites: What Site Coordinators Need to Know

Small investigator sites face the same FDA 21 CFR Part 11 obligations as large sponsors — but with fewer resources. This practical guide covers the six document types that require compliant e-signatures at research sites, what sponsors check during site qualification, the non-repudiation letter requirement, and a three-SOP framework for sites without a dedicated QA team.

May 9, 202611 min read
Regulatory Compliance

FDA Part 11 Non-Repudiation Letter: What It Is, How to Write It, and Where to Submit

Under 21 CFR 11.100(c), any organization using electronic signatures in FDA-regulated activities must certify in writing to FDA that those signatures are legally binding. Updated May 2026: the FDA ESG NextGen Unified Submission Portal now requires electronic upload of non-repudiation agreements during account registration — physical mailing is no longer required for new ESG accounts. This guide covers who must submit, what the letter must say, the new portal process, whether one letter covers all studies, and what CROs need to know.

May 6, 202611 min read
Regulatory Compliance

ALCOA++ Data Integrity: Understanding the Tenth Principle for Pharmaceutical Audit Trails

ALCOA++ adds a tenth data integrity principle — Traceable — to the familiar ALCOA+ framework. This guide covers what Traceable requires for pharmaceutical audit trail software, the EU GMP Chapter 4 ALCOA++ codification approaching finalization, the EMA-PIC/S joint consultation on data integrity alignment, and what multi-regional organizations must do to satisfy both FDA and EU requirements simultaneously. Updated June 2026: EU GMP Annex 11 Clause 9 audit trail lifecycle expansion now approaching enforcement window.

May 4, 202612 min read
Regulatory Compliance

Electronic Signature SOPs: What FDA Part 11 Requires and How to Write Them

FDA 21 CFR Part 11 Section 11.10(j) explicitly requires written policies holding individuals accountable for their electronic signatures. This guide covers the six SOPs every Part 11 system needs, what FDA investigators check during SOP audits, and how to structure each procedure.

May 3, 202613 min read
Regulatory Compliance

21 CFR Part 11 Electronic Signature Validation: IQ OQ PQ Step-by-Step Guide

A practical guide to IQ, OQ, and PQ validation for 21 CFR Part 11 e-signature systems, including CSA's risk-based approach, specific test cases for each Part 11 control, and what FDA investigators look for.

April 27, 202612 min read
Clinical Trials

Electronic Signatures for CROs: What Contract Research Organizations Need for Part 11 Compliance

CROs are explicitly named as regulated entities in the October 2024 FDA guidance, with Part 11 obligations enforceable through the sponsor-CRO written agreement. This guide covers the non-repudiation letter requirement, dual-site accountability, TMF e-signature requirements for CRO monitoring workflows, delegation of authority log management across multi-site environments, and system qualification responsibility.

April 20, 202612 min read
Clinical Trials

Clinical Trial Document Management: E-Signature Requirements for Sites and Sponsors

Managing clinical trial documents with e-signatures requires a framework that satisfies FDA 21 CFR Part 11, ICH E6(R3), and the October 2024 FDA final guidance. This guide covers the documents sites and sponsors must sign, delegation of authority log requirements, TMF retention obligations, and platform evaluation criteria.

April 13, 202613 min read
Buyer's Guide

What Makes an E-Signature Platform FDA Compliant? The Complete Technical Checklist

Every e-signature vendor claims FDA compliance. This guide explains what Part 11 Subpart B and Subpart C actually require at the technical level -- hash-chained audit trails, authentication at signing, signature meaning, tamper-evident records, and validation documentation -- plus a 14-question checklist to run against any vendor. Updated June 2026: applicability assessment added as Step 1 of any FDA compliance evaluation.

April 10, 202615 min read
Regulatory Compliance

E-Signatures for Pharmaceutical QA: Batch Records, SOPs, and Deviation Reports

Pharmaceutical QA signatures on batch records, SOPs, deviations, and CAPA reports must meet FDA 21 CFR Part 11 and Part 211 requirements. This guide covers the electronic signature workflow for QA release and batch disposition sign-off, reason-for-change obligations, audit trail review before lot release, SOP routing enforcement, and the critical differences between general e-signature tools and purpose-built GMP platforms. Updated June 2026 with the QA batch release sign-off workflow and EU GMP Annex 11 finalization obligations.

April 10, 202614 min read
Regulatory Compliance

GxP Electronic Signature Requirements: What GMP, GLP, and GCP Each Demand

GMP, GLP, and GCP all require FDA 21 CFR Part 11 compliance for electronic signatures, but each discipline adds specific obligations on top of the shared foundation. This guide compares what each GxP discipline requires -- from GCP non-repudiation letters and delegation of authority logs to GLP study director designations and GMP per-batch audit trail reviews. Updated June 2026: EU GMP Annex 11 Clause 3 supplier qualification requirement now applies to all GMP-regulated e-signature deployments.

April 7, 202614 min read
Regulatory Compliance

21 CFR Part 11 Compliant Electronic Records: Subpart B Requirements Explained

Subpart B of FDA 21 CFR Part 11 defines the requirements for compliant electronic records, covering validation, audit trails, access controls, record retention, and signature-to-record linking. This guide explains each section of Subpart B, common FDA 483 failures, and what the 2024 clinical investigations guidance changed for cloud-based systems. Updated June 2026: Part 11 applicability assessment framework added -- which systems must meet Subpart B and why the determination must be documented.

April 6, 202612 min read
Regulatory Compliance

FDA Inspection Readiness: Audit Trail Requirements and the Pre-Inspection Checklist (2026)

What FDA investigators actually request during an audit trail review, the most common 483 findings, and a practical pre-inspection checklist for 2026.

April 4, 202613 min read
Buyer's Guide

Choosing the Best E-Signature for Clinical Trials: 8 Requirements

What makes an e-signature platform right for clinical trials? This guide covers the 8 specific requirements drawn from 21 CFR Part 11, the FDA's 2024 final guidance, ICH E6(R3), and EU CTR 536/2014 — including guest signing, delegation of authority logs, IQ/OQ validation docs, and 25-year retention.

March 30, 202611 min read
Regulatory Compliance

Electronic Signature Audit Trail Requirements: 21 CFR Part 11, Annex 11, and ALCOA+

What does FDA actually require for electronic signature audit trails -- and what is changing before Annex 11 finalizes? This guide covers 21 CFR Part 11 Section 11.10(e), EU GMP Annex 11 Clause 9 scope expansion (exports and archival events now loggable), ALCOA+ audit trail requirements, the audit trail review gap FDA inspectors specifically targeted in 2025-2026 enforcement, and the most common 483 audit trail failures at pharmaceutical and biotech sites.

March 30, 202612 min read
Regulatory Compliance

ALCOA+ Audit Trail Software Requirements: Complete Life Sciences Guide (2026)

What does ALCOA+ compliant audit trail software actually need to do? This guide covers the 8 core technical requirements, the ALCOA++ Traceable principle, EU GMP Chapter 4 ALCOA++ codification nearing finalization, the EMA-PIC/S joint consultation on data integrity, and 2026 FDA inspection enforcement trends showing audit trail findings in over 30% of regulated software inspections. Updated June 2026: EU GMP Annex 11 finalization approaching — Clause 9 audit trail scope expansion adds export and archival events to the required log, raising the implementation bar beyond what most current audit trail systems cover.

March 27, 202611 min read
Buyer's Guide

Best 21 CFR Part 11 Compliant E-Signature Software (2026): What Actually Matters

Most vendors claim 21 CFR Part 11 compliance. Few can prove it. Here are the 7 technical requirements that separate real compliance from marketing claims.

March 27, 202612 min read
Regulatory Compliance

Part 11 Electronic Signatures: Requirements, Components, and Common Mistakes

A practical guide to 21 CFR Part 11 electronic signature requirements -- Subpart B and Subpart C explained, common compliance failures at clinical research sites, and what FDA inspectors look for in 2026.

March 23, 20269 min read
Data Privacy

Electronic Signatures and GDPR Compliance: Full Guide

E-signature workflows process personal data (names, emails, IPs) subject to GDPR. This guide covers lawful bases under Article 6, data minimization, DPA requirements, cross-border transfers, data subject rights, retention policies, and a 12-point compliance checklist.

March 16, 20269 min read
Regulatory Compliance

FDA Warning Letters Are Up 73%. Is Your Audit Trail Ready?

FDA warning letters jumped 73% in H2 2025. Here's what clinical trial sponsors and CROs need to know about Part 11 audit trails before your next inspection.

March 16, 20268 min read
Regulatory Compliance

ALCOA+ Data Integrity: 9 Principles for Life Sciences

ALCOA+ violations show up in most FDA data integrity warning letters. Here's what each of the 9 principles requires for electronic records and audit trails.

March 14, 202610 min read
Regulatory Compliance

Audit Trails in Regulated Industries: Complete Guide

Audit trails are now the most-cited category in FDA Part 11 483 observations -- and EU GMP Annex 11 Clause 9 is expanding what must be logged before the 2026 finalization window. This guide covers FDA 21 CFR Part 11 Section 11.10(e), Annex 11 Clause 9 scope expansion (exports and archival now loggable), hash chain verification, the audit trail review gap FDA inspectors now specifically target, and implementation best practices for pharma, biotech, and CROs.

March 13, 202610 min read
Clinical Trials

EU Clinical Trial Regulation 536/2014: Sponsor Guide

EU CTR 536/2014 replaced the Clinical Trials Directive with a harmonized CTIS-based framework. All EU clinical trials have operated under the full regulation since January 2025, and the 2026 CTIS enforcement review is underway. This guide covers Article 58 25-year retention obligations, the single CTIS submission process, e-signature requirements for cross-border trials, EU GMP Annex 11 implications for EU trial site electronic records, and 2026 compliance checkpoints for sponsors, CROs, and investigator sites. Updated June 2026 with the Annex 11 finalization timeline and what changes before it takes effect.

March 12, 202611 min read
Buyer's Guide

DocuSign Part 11 Module vs Purpose-Built Compliance Platforms

DocuSign addresses FDA 21 CFR Part 11 through a paid add-on module. Purpose-built platforms embed compliance controls natively. This guide compares the two architectures across audit trails, 2FA, validation burden, total cost of ownership, and organizational fit for life sciences. Updated June 2026 with EU GMP Annex 11 Clause 3 supplier qualification implications for vendor selection.

March 11, 202611 min read
Buyer's Guide

How to Validate an E-Signature System: IQ/OQ/PQ Under CSA

Learn how to validate an e-signature system using IQ/OQ/PQ under FDA's 2025 Computer Software Assurance (CSA) guidance. Covers risk-based testing, Part 11 mapping, qualification checklists, change control, and common validation pitfalls for pharma, biotech, and medical device companies. Updated June 2026: Part 11 applicability assessment is now a required prerequisite before validation scope can be determined.

March 11, 202612 min read
Buyer's Guide

E-Signature Vendor Evaluation Checklist: RFP Questions for Regulated Life Sciences

40+ RFP questions for evaluating e-signature vendors in pharma, biotech, and CROs. Covers FDA 21 CFR Part 11, EU GMP Annex 11, and ALCOA+ data integrity requirements with a weighted scoring template.

March 11, 202616 min read
Regulatory Compliance

FDA Warning Letters & Data Integrity: Lessons from Real Enforcement Actions

Data integrity deficiencies appear in 60-80% of FDA drug GMP warning letters, and enforcement continued into 2026. This guide examines real warning letters citing shared logins, missing audit trails, backdated batch records, absent training documentation, and audit trails that were generated but never reviewed before lot release -- with outcomes including consent decrees, import bans, and criminal referrals. Updated June 2026 with the audit trail review documentation gap as the fastest-growing FDA inspection finding category in pharmaceutical manufacturing.

March 11, 202613 min read
Clinical Trials

Decentralized Clinical Trials & eConsent: E-Signature Requirements

Decentralized clinical trials (DCTs) use telehealth and direct-to-patient technologies for remote trial conduct. This guide covers the FDA's September 2024 DCT guidance, eConsent best practices, e-signature compliance under Part 11 and ICH E6(R3), and data integrity for remote workflows.

March 11, 202611 min read
Buyer's Guide

How to Migrate to a Part 11 E-Signature Platform: 6-Phase Framework

Migrating from paper or legacy systems to a 21 CFR Part 11 compliant e-signature platform requires structured change control. This guide covers a six-phase migration framework: requirements, validation, pilot, parallel running, cutover, and decommission — with audit trail continuity and training strategies.

March 11, 202612 min read
Regulatory Compliance

Medical Device E-Signatures Under QMSR, ISO 13485 & EU MDR

The FDA's QMSR replaced the QSR on February 2, 2026, and the first QMSR inspection cycle is now underway. This guide covers how e-signatures interact with the new QMSR, Part 11's independent requirements, ISO 13485:2016 design controls and electronic records, EU MDR documentation obligations, and what medical device companies now face in their first QMSR implementation year -- including quality system changes that require re-validation of existing e-signature workflows.

March 11, 202613 min read
Regulatory Compliance

AI & Electronic Signatures in Regulated Industries: Compliance Guide

AI is transforming e-signature workflows in life sciences — from intelligent document routing to anomaly detection and predictive compliance. This guide covers the FDA's AI guidance, EU AI Act high-risk classification, Part 11 implications, and a risk-based framework for adopting AI-enhanced compliance tools.

March 11, 202613 min read
Buyer's Guide

CSV vs CSA: Computer System Validation vs Software Assurance Explained

FDA's Computer Software Assurance (CSA) guidance, finalized September 2025, replaces traditional CSV with risk-based validation. This guide compares CSV and CSA approaches, explains risk classification for e-signature functions, and provides practical transition strategies for life sciences organizations. Updated June 2026: CSA risk categorization and Part 11 applicability assessment are now complementary -- both must be completed before validation scope is determined.

March 11, 202613 min read
Regulatory Compliance

EU GMP Annex 11 (2025 Draft): Computerized Systems Compliance Guide

The 2025 draft revision of EU GMP Annex 11 expands from 5 to 19 pages, adding MFA at signing (Clause 12.1), expanded audit trail scope covering exports and archival (Clause 9), and an Annex 11 compliant release workflow requirement for batch disposition documentation. Updated June 2026: finalization window now active. Covers key changes to batch release audit trail review obligations, FDA Part 11 comparison, Qualified Person electronic signature requirements, and preparation steps before the 2025 draft takes effect.

March 11, 202613 min read
Buyer's Guide

How to Choose an E-Signature Platform for Life Sciences

Evaluating e-signature platforms for pharma, biotech, and medical devices? This guide covers FDA 21 CFR Part 11 compliance, audit trail capabilities, 2FA requirements, validation documentation, red flags to avoid, and total cost of ownership for regulated industries. Updated June 2026: new section on EU GMP Annex 11 Clause 3 supplier qualification as a required vendor selection criterion for GMP-regulated organizations.

March 10, 202611 min read
Healthcare

HIPAA-Compliant Electronic Signatures: Requirements Guide

HIPAA allows electronic signatures but requires BAAs, encryption (AES-256), audit controls, and MFA for documents containing PHI. This guide covers Security Rule safeguards, BAA requirements, audit trails, and best practices for healthcare organizations. Updated June 2026: covers the March 2026 CMS final rule establishing the first HIPAA-adopted standard for electronic signatures in claims attachments.

March 6, 20269 min read
Regulatory Compliance

eIDAS vs ESIGN Act: Complete Comparison Guide (2026)

eIDAS 2.0 is expanding qualified trust services while the ESIGN Act stays technology-neutral. This guide compares the two frameworks on legal validity, signature tiers (SES/AES/QES), cross-border recognition, a 7-row document-type tier decision table for life sciences, June 2026 EU Digital Identity Wallet pilot implications for clinical trial sites, and what multinational regulated organizations must do to satisfy both.

March 3, 20269 min read
Regulatory Compliance

GxP Compliance for Electronic Records: GLP, GMP, GCP Guide

What GxP compliance actually requires for electronic records under GMP, GLP, GCP, and EU Annex 11, with ALCOA+ principles and validation basics explained.

February 28, 202610 min read
Clinical Trials

Electronic Signatures in Clinical Trials: 2024 FDA Guidance Update

The FDA finalized 29 Q&As on electronic systems in clinical investigations in October 2024, resolving ambiguities around non-repudiation letters, hybrid records, cloud platforms, and risk-based validation. This guide explains what changed and what it means for sponsors, CROs, and research sites. Updated June 2026 with ICH E6(R3) final implementation status, FDA ESG NextGen portal update, and EU GMP Annex 11 2025 draft MFA implications for EU trial sites.

February 25, 202614 min read
Regulatory Compliance

FDA 21 CFR Part 11: Complete Compliance Guide (2026)

What FDA 21 CFR Part 11 actually requires for electronic records and signatures, explained in plain terms with real 483 examples and 2026 updates.

February 21, 202612 min read
Fundamentals

Digital Signatures vs Electronic Signatures: Key Differences

Digital signatures use PKI cryptography to verify identity and detect tampering. Electronic signatures are broader, covering any electronic intent to sign. Learn when to use each in regulated industries like pharma and healthcare.

February 18, 20268 min read
Fundamentals

What Are Electronic Signatures? Definition, Types & Legal Validity

Electronic signatures (e-signatures) are legally binding electronic indications of intent to sign a record. Learn how they work, their legal validity under ESIGN and eIDAS, the three types (SES, AES, QES), and why regulated industries need compliant solutions.

February 15, 202610 min read

Ready for Compliant E-Signatures?

Start your free trial and see how Klyverity meets compliance requirements for your regulated industry.

Start Free TrialView Compliance